149 related articles for article (PubMed ID: 27031354)
1. Intrinsic Subtypes of Primary Breast Cancer--Gene Expression Analysis.
Schmidt M; Thomssen C; Untch M
Oncol Res Treat; 2016; 39(3):102-10. PubMed ID: 27031354
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
Duffy MJ; Harbeck N; Nap M; Molina R; Nicolini A; Senkus E; Cardoso F
Eur J Cancer; 2017 Apr; 75():284-298. PubMed ID: 28259011
[TBL] [Abstract][Full Text] [Related]
3. [A Review Multigene Assays for Clinical Utility in Breast Cancer].
Araki K; Ito Y
Gan To Kagaku Ryoho; 2016 Nov; 43(11):1332-1340. PubMed ID: 27899774
[TBL] [Abstract][Full Text] [Related]
4. Multigene prognostic tests in breast cancer: past, present, future.
Győrffy B; Hatzis C; Sanft T; Hofstatter E; Aktas B; Pusztai L
Breast Cancer Res; 2015 Jan; 17(1):11. PubMed ID: 25848861
[TBL] [Abstract][Full Text] [Related]
5. Genomic subtypes in choosing adjuvant therapy for breast cancer.
Zelnak AB; O'Regan RM
Oncology (Williston Park); 2013 Mar; 27(3):204-10. PubMed ID: 23687790
[TBL] [Abstract][Full Text] [Related]
6. Genomic predictors of outcome and treatment response in breast cancer.
Dunn L; Demichele A
Mol Diagn Ther; 2009; 13(2):73-90. PubMed ID: 19537843
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer classification: linking molecular mechanisms to disease prognosis.
Taherian-Fard A; Srihari S; Ragan MA
Brief Bioinform; 2015 May; 16(3):461-74. PubMed ID: 24950687
[TBL] [Abstract][Full Text] [Related]
8. [Gene signatures for breast cancer, clinical utility and therapeutic applications].
Vargas-Aguilar VM; Arroyo-Alvarez K
Rev Med Inst Mex Seguro Soc; 2018; 56(2):180-185. PubMed ID: 29906029
[TBL] [Abstract][Full Text] [Related]
9. Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany.
Lux MP; Minartz C; Müller-Huesmann H; Sandor MF; Herrmann KH; Radeck-Knorre S; Neubauer AS
Cancer Treat Res Commun; 2022; 31():100519. PubMed ID: 35093682
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling in breast cancer.
Morris SR; Carey LA
Rev Endocr Metab Disord; 2007 Sep; 8(3):185-98. PubMed ID: 17464566
[TBL] [Abstract][Full Text] [Related]
11. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
12. Impact of breast cancer subtypes and patterns of metastasis on outcome.
Kast K; Link T; Friedrich K; Petzold A; Niedostatek A; Schoffer O; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
Breast Cancer Res Treat; 2015 Apr; 150(3):621-9. PubMed ID: 25783184
[TBL] [Abstract][Full Text] [Related]
13. Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.
Tsai ML; Lillemoe TJ; Finkelstein MJ; Money JE; Susnik B; Grimm E; Kang SH; Swenson KK
Clin Breast Cancer; 2016 Feb; 16(1):45-50. PubMed ID: 26385397
[TBL] [Abstract][Full Text] [Related]
14. Gene Expression Assay in the Management of Early Breast Cancer.
Caputo R; Cianniello D; Giordano A; Piezzo M; Riemma M; Trovò M; Berretta M; De Laurentiis M
Curr Med Chem; 2020; 27(17):2826-2839. PubMed ID: 31804159
[TBL] [Abstract][Full Text] [Related]
15. Biomolecular features of clinical relevance in breast cancer.
Daidone MG; Paradiso A; Gion M; Harbeck N; Sweep F; Schmitt M
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S3-14. PubMed ID: 15095022
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
[TBL] [Abstract][Full Text] [Related]
17. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
Bergamaschi A; Kim YH; Wang P; Sørlie T; Hernandez-Boussard T; Lonning PE; Tibshirani R; Børresen-Dale AL; Pollack JR
Genes Chromosomes Cancer; 2006 Nov; 45(11):1033-40. PubMed ID: 16897746
[TBL] [Abstract][Full Text] [Related]
18. Translating Research into Practice: the Prosigna® (PAM50) Gene Signature Assay.
Boccia RV
Clin Adv Hematol Oncol; 2015 Jun; 13(6 Suppl 6):3-13. PubMed ID: 26191941
[TBL] [Abstract][Full Text] [Related]
19. Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis.
Wu YM; Hu W; Wang Y; Wang N; Gao L; Chen ZZ; Zheng WQ
Breast Cancer Res Treat; 2013 Aug; 141(1):23-32. PubMed ID: 23933801
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of multigene profiling assays in early-stage breast cancer.
Chang MC; Souter LH; Kamel-Reid S; Rutherford M; Bedard P; Trudeau M; Hart J; Eisen A;
Curr Oncol; 2017 Oct; 24(5):e403-e422. PubMed ID: 29089811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
